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Cardiovascular disease (CVD) is now the leading cause of death globally and is a growing health concern. Dietary factors are
important in the pathogenesis of CVD and may to a large degree determine CVD risk, but have been less extensively investigated.
Functional foods are those that are thought to have physiological beneﬁts and/or reduce the risk of chronic disease beyond their
basicnutritionalfunctions.Thefoodindustryhasstartedtomarketproductslabelledas“functionalfoods.”Althoughmanyreview
articles have focused on individual dietary variables as determinants of CVD that can be modiﬁed to reduce the risk of CVD, the
aim of this current paper was to examine the impact of functional foods in relation to the development and progression of CVD.
Epidemiologicstudieshavedemonstratedtheassociationbetweencertaindietarypatternsandcardiovascularhealth.Researchinto
thecardio-protectivepotentialoftheirdietarycomponentsmightsupportthedevelopmentoffunctionalfoodsandnutraceuticals.
This paper will also compare the eﬀect of individual bioactive dietary compounds with the eﬀect of some dietary patterns in terms
of their cardiovascular protection.
1.Introduction
Cardiovascular disease (CVD) is now the leading cause
of death globally and is a growing health concern [1].
Lifestyle-related conditions, such as obesity, hyperlipidemia,
type 2 diabetes, and hypertension, are also widespread
and becoming more prevalent globally [2]. Although the
traditional cardiovascular risk factors (Table 1)h a v eb e e n
extensively investigated, dietary factors are also important in
thepathogenesisofCVDandmaytoalargedegreedetermine
CVD risk factors such as blood pressure and dyslipidaemia,
but have been less extensively investigated.
Theroleofdietaryfactorshasbeenlargelyinvestigatedby
reducing the content of speciﬁc food component known to
increase risk, that is, sodium or saturated fats [3]o rb yl a r g e
longitudinal cohort studies in which baseline dietary intake
was related to cardiovascular outcomes [4, 5].
The term “functional foods” has been commonly used
in marketing but still lacks a ﬁrm regulatory deﬁnition
[6]. Functional foods are those that are thought to have
physiological beneﬁts and/or reduce the risk of chronic
diseasebeyondtheirbasicnutritionalfunctions[7].Thefood
industry has started to market products with a “functional
food” label. Whilst the beneﬁts of some functional food
constituents may be perceived to enhance short-term well-
being, the beneﬁts are generally related to the long-term
mitigation of certain diseases.
Although many review articles have focused on individ-
ual dietary variables as major determinants of CVD that can
be modiﬁed in order to reduce the risk of CVD, the aim of
this current paper was to examine the impact of functional
foods in relation to the development and progression of
CVD. Epidemiologic studies have long demonstrated the
association between certain dietary patterns and cardiovas-
cular health. Research into the cardioprotective potential
of their dietary components may support the development
of functional foods and nutraceuticals. This paper will
also compare the eﬀect of individual bioactive dietary
compounds with the eﬀect of some dietary patterns in terms
of their cardiovascular protection.2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 1:Theantioxidantdefensesystemcomprise,endogenousenzymaticandexogenousnonenzymaticnutrients.Thedietaryantioxidant
nutrients can either be water soluble or lipid soluble. There are also other dietary constituents that may have either direct antioxidant activity
or indirect antioxidant activity such as trace elements that are constituents of antioxidant enzymes.
Table 1: Cardiovascular risk factors.
Category Examples
Nonmodiﬁable risk
factors
Advancing age
Male gender
Family history/genotype
Metabolic risk factors
Hypertension
Hyperlipidemia
Diabetes mellitus
Metabolic syndrome
Obesity/overweight
Lifestyle risk factors
Diet
Smoking
Physical activity
Novel risk factors
Elevated homocysteine level
Elevated lipoprotein (a) level
Small dense LDL-C
Elevated inﬂammatory markers levels
Elevated hemostatic factors levels
2.The ProtectiveEffect of DietinCVD
It has been proposed that CVD can be prevented by lifestyle
changes, including diet [8]. Early evidence for the role of diet
on CVD came from data on trends in food consumption,
and ecological studies has shown associations between CVD
prevalence and fat intake [3]. Moreover, excessive con-
sumption of foods that are caloriedense, nutritionally poor,
highlyprocessed,andrapidlyabsorbablecanleadtosystemic
inﬂammation, reduced insulin sensitivity, and a cluster of
metabolic abnormalities, including obesity, hypertension,
dyslipidemia, and glucose intolerance [9]. More recently,
there has been a focus in nutrition research to try and
understand the eﬀects of whole foods [10]. An integrated
approach combining lifestyle modiﬁcation with the correct
pharmacologic treatment is sought to reduce cardiovascular
risk factors, to improve vascular health, and to reduce
healthcare expenditure [11].
Whilst epidemiological studies have identiﬁed a rela-
tionship between diet and CVD, there is still considerable
scientiﬁc uncertainty about the relationship between speciﬁc
dietary components and cardiovascular risk. Observational,
prospective cohort studies suggest that a higher dietary
intake or supplementation of antioxidants is associated with
a lower risk of CVD and mortality, but the evidence from
clinical trials is still largely negative [12]. The conﬂicting
results between the apparent protective eﬀects of nutrients
as part of dietary intake and the lack of eﬀectiveness of single
nutrientsupplementationintrialshasledtoafocusonwhole
foods or modiﬁed diets as protective against CVD [13].
Oxidative stress may be deﬁned as a disturbance in the
pro-oxidant/antioxidant balance that favours oxidation. It
has been suggested that oxidative stress is involved in the
etiology of several chronic diseases including CVD, diabetes,
stroke, some cancers, and neurodegenerative disorders [14].
Dietary nutrients, both water soluble and lipid soluble,
comprise an important aspect of the antioxidant defense
system (Figure 1).J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
Beyond their normal occurrence in cells and tissues of
living organisms, free radicals and reactive species are also
produced in the foods people consume every day, inducing
undesirable reactions like oxidation of lipids, proteins,
nucleic acids, and carbohydrates.
An impaired capacity to scavenge free radicals and
reactive species as a consequence of decreased levels of
antioxidant cellular defense systems or excessive free radicals
production is common in brain, liver, heart, and other
important target organs in humans and animals [15, 16].
It was initially thought that antioxidant vitamins would
have represented a simple approach to counteract increased
oxidative stress by cardiovascular risk factors. Nonetheless,
high doses of some antioxidant vitamins were found to
exert adverse vascular eﬀects. The eﬀects of antioxidant
supplements on all-cause mortality of adults included in
primary and secondary prevention trials, by treatment with
betacarotene,vitaminA,andvitaminE,mayindeedincrease
mortality, and the potential role of vitamin C and selenium
on mortality needs further study [17, 18].
3.FunctionalFoods
The notion that foods not only provide basic nutrition
but can also prevent diseases and ensure good health
and longevity is now attained greater prominence [19].
Various terms have been used interchangeably to designate
foods for disease prevention and health promotion. The
term Nutraceuticals was introduced in 1989 by the US
Foundation for Innovation in Medicine and referred to “any
substance that is a food or a part of a food and provides
medical or health beneﬁts, including the prevention and
treatment of disease” [20]. The interest in nutraceuticals
for cardiovascular prevention was particularly stimulated
after the observations of a close association between the
consumption of particular dietary factors, as indicated by
higher plasma levels [21, 22], and a reduced cardiovascular
event rate. In 1994, the US Institute of Medicine’s Food and
Nutrition Board deﬁned functional foods as “any food or
food ingredient that may provide a health beneﬁt beyond the
traditional nutrients it contains” [6, 7, 23].
4.FunctionalFoodswith
Health-Related Properties
The conﬂicting results between the apparent protective
eﬀects of nutrients as part of entire food intake and the
lack of eﬀectiveness of single nutrient supplementation in
t r i a l sh a sl e dt oaf o c u so nw h o l ef o o d sa sp r o t e c t i v e
against CVD. Populations consuming a large proportion of
plant-based foods, including fruits and vegetables, or those
with high intake of seafood are known to have a lower
incidence of CVD and certain types of cancer [24]. Based
on these ﬁndings, considerable interest has been expressed
by manufacturers, consumers, and health professionals in
functional foods and nutraceuticals.
Functional foods, containing physiologically active com-
ponents either from plant or animal sources, marketed
with the claim of their ability to reduce heart disease risk
focusing primarily on established risk factors, that is, blood
cholesterol, diabetes, and hypertension. Functional foods
are suspected to exert their cardioprotective eﬀects mainly
through lipid lowering eﬀects, antioxidant actions, and/or
decreased homocysteine levels (Table 2).
Vegetable and fruit ﬁbers (with pectin), garlic and oily
seeds (walnut, almonds, etc.), and ﬁsh oils have lipid-
lowering eﬀects in humans, through both inhibition of fat
absorption and suppression of hepatic cholesterol synthesis.
Homocysteine increases the risk of both cardiovascular
and cerebrovascular disorders [25] by enhancing arteriolar
constriction and decreasing endothelial vasodilation [26]. A
higher intake of folate, antioxidant vitamins, whole grains,
and phytochemicals has been reported to abrogate the
deleterious vascular eﬀects of homocysteine in the heart [27,
28]. A signiﬁcant cardiovascular beneﬁt of phytochemicals
(polyphenols in wine, grapes, and teas), vitamins (ascorbate,
tocopherol), and minerals (selenium, magnesium) in foods
[19, 29] is thought to be the capability of scavenging free
radicals produced during atherogenesis.
Several functional foods are thought to be of beneﬁt in
treating and preventing CVD. The most common functional
foods that have been studied in cardiovascular patients are
long-chain n-3 fatty acids, dietary ﬁber, and phytochemicals
as well as nutrients based on or enriched with vegetable
proteins, mainly soy.
4.1.Fish. Peoplewithahighintakeofdietaryﬁshandﬁshoil
supplements have a low rate of CVD [30, 31]. Although ﬁsh
per se contains various nutrients with potentially favourable
eﬀects on health, attention has been particularly focused on
the omega-3 (n-3) fatty acids. n-3 fatty acids also include the
plant-derived alpha-linolenic acid (ALA, 18:3 n-3), eicosa-
pentaenoic acid (EPA, 20:5 n-3), and docosahexaenoic acid
(DHA, 22:6 n-3). Both EPA and DHA are found in oily
ﬁsh, such as salmon, lake trout, tuna, and herring, and ﬁsh-
derived products (ﬁsh oils). n-3 fatty acids precursor, α-
linolenic acid, is typically found in various plants (e.g., spin-
ach), seeds (nuts and ﬂaxseeds), and oils derived from them.
Generally,verylittleALAisconvertedtoEPA,andevenlessto
DHA, and therefore direct intake of the latter two is optimal.
Despite the established beneﬁcial eﬀect of fatty ﬁsh
consumption on CHD, the species and amount of ﬁsh
consumed,aswellasthepreparationmethod,haveanimpact
on CHD risk [32]. The concomitance of low amounts of n-3
fatty acids in our average diet and the need for prolonged
administration for prevention and treatment has led to
the development of selected preparations (enriched foods
or special formulations, e.g., n-3 fatty acids incorporated
into cows’ milk). These should combine acceptability and
adequatebioavailabilityoftheirrelativelylowcontentsofn-3
fatty acids. These fatty acids are therefore being incorporated
into a number of commercially available, natural foods that,
due to rather their structural features, appear to be partic-
ularly suited as eﬃcient fatty acid vehicles [33]. Further-
more, some environmental contaminants found in certain
ﬁsh,forexample,methylmercury,polychlorinatedbiphenyls,
and dioxins, may diminish the health beneﬁts of ﬁsh-derived
n-3 fatty acids [34].4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 2: Potential cardiovascular protective eﬀects of functional foods.
Functional foods Bioactive compounds Potential mechanism References
-N u t s - Tocopherols, omega-3 fatty
acids
Lowering blood cholesterol
Sabate and Ang [60]
Albert et al. [62]
- Legumes - Fiber and polyphenols Erkkil¨ a and Lichtenstein [55]
- Fruits and vegetables - Fiber (pectin) Liu et al. [56]
- Margarine - Phytosterols Darmadi-Blackberry et al. [63]
- Fish oil - Omega-3 fatty acids Hicks and Moreau [110]
- Whole grains - Fiber and phytochemicals Dyerberg et al. [37]
- Soy proteins - Genistein and daidzein Lutsey et al. [73]
- Dark chocolate - Flavonoid
Anderson et al. [78]
Harland and Haﬀner [79]
Grassi et al. [89]
Baba et al. [90]
- Fish - Omega-3 fatty acids
Inhibition of LDL-C
oxidation
Lee and Wander [39]
- Green leafy vegetables, fruits - Carotenoids Chopra et al. [52]
- Citrus fruits and vegetables - Vitamin C Sesso et al. [119]
- Tomato - Lycopene Aguirre and May [115]
- Extravirgin olive oil - Polyphenolics and oleic acid Engelhard et al. [123]
- Green tea - Tea polyphenolics Psaltopoulou et al. [145]
- Soy proteins - Genistein, daidzein, and
glycitein Wiseman et al. [81]
- Dark chocolate - Flavonoid Grassi et al. [89]
- Pomegranate - Polyphenols Davidson et al. [99]
- Fish - Omega-3 fatty acids Lowering blood triglycerides
Durrington et al. [36]
Dyerberg et al. [37]
Harris et al. [40]
- Fish - Omega-3 fatty acids Mozaﬀarian [35]
- Legumes - Fiber He et al. [53]
- Whole grains - Fiber and phytochemicals Savica et al. [54]
Lee et al. [65]
- Citrus fruits - Ascorbic acid Flint et al. [72]
Decreasing blood pressure
- Ginseng - Ginsenosides
Hooper et al. [108]
- Onion and garlic - Quercetin
- Green and black teas - Tea polyphenols
- Grapes and red wines - Grape polyphenols Perez-Jimenez and Saura-Calixto [160]
- Dark chocolate - Flavonoid Grassi et al. [89]
- Fruits and vegetables - Folate
- Phytochemicals
Lowering blood
homocysteine
Samman et al. [144]
Appel et al. [152]
- Whole grains - Fiber and phytochemicals Jenkins et al. [154]
- Citrus fruits and vegetables - Vitamin C Broekmans et al. [27]
- Nuts, seeds, and oils - Vitamin E
-T o m a t o e s -L y c o p e n e
Antioxidant action
Engelhard et al. [123]
Krinsky and Johnson [121]
Sesso et al. [119]
Aguirre and May [115]
- Green leafy vegetables, fruits - Carotenoids
- Vegetable oils - Tocopherol, tocotrienols
- Citrus fruits and vegetables - Vitamin C
Mink et al. [105]
Perez-Jimenez and
Saura-Calixto [160]
- Soy proteins - Genistein and daidzein
- Green and black teas - Tea polyphenols
- Grapes and red wines
- Anthocyanins, catechins,
cyanidins, and ﬂavonols,
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Table 2: Continued.
Functional foods Bioactive compounds Potential mechanism References
- Nuts, seeds, and oils - Vitamin E
Anti-inﬂammatory action
Singh et al. [128]
Kushi et al. [130]
- Fish - Omega-3 fatty acids Ueeda et al. [38]
- Legumes - Polyphenols Lutsey et al. [73]
- Grapes and red wines
- Anthocyanins, catechins,
cyanidins, and ﬂavonols,
myricetin, and quercetin
Perez-Jimenez and Saura-Calixto [160]
- Fish - Omega-3 fatty acids
Endothelial function
Ueeda et al. [38]
- Nuts - Polyphenols Ros et al. [61]
- Citrus fruits and vegetables - Vitamin C Aguirre and May [115]
- Grapes and red wines
- Anthocyanins, catechins,
cyanidins, and ﬂavonols,
myricetin, and quercetin
Perez-Jimenez and Saura-Calixto [160]
- Dark chocolate - Flavonoid Grassi et al. [88]
- Grapes and red wines
- Anthocyanins, catechins,
cyanidins, and ﬂavonols,
myricetin and quercetin
Platelets aggregation Perez-Jimenez and Saura-Calixto [160]
Mink et al. [105]
Potential mechanisms for the cardiovascular protec-
tive eﬀects of n-3 fatty acids are suggested to be; anti-
inﬂammatory, antithrombotic (reduced platelet aggregabil-
ity), and antiarrhythmic (reducing the risk of potentially
fatal cardiac arrhythmias), lowering of heart rate and blood
pressure, hypotriglyceridemic, and improved endothelial
function [35].
Fish oil supplements have favorable eﬀects on lipid
proﬁle and blood pressure [36, 37]. The former appears
to be due to decreased hepatic triglyceride secretion com-
bined with enhanced clearance of triglycerides from plasma.
Moreover, ﬁsh ingestion has been related to a reduced risk
for myocardial infarction, which may relate to beneﬁcial
eﬀects of EPA and DHA on plaque stability (probably related
to the content of inﬂammatory cells) and modulation of
endothelial function [38]. EPA and DHA have also been
shown to lower low-density lipoprotein (LDL) oxidative
susceptibility in postmenopausal women, which could help
to reduce the risk of CVD [39]. Primary among these is
the reduction of serum triglycerides [40]. While research
interests in the eﬀects of n-3 fatty acids have been focused
mainly on the long-chain compounds (EPA and DHA), the
roleofn-3ALAshouldalsobeconsidered.Dataontheeﬀects
of ALA on CVD outcomes are somewhat limited [41, 42], as
some researchers suggest potential cardiovascular protection
by this unsaturated fatty acid [43].
A meta-analysis of 65 studies demonstrated that n-3
fatty acids lowered triglycerides levels in a dose-dependent
manner, with the triglycerides lowering being proportional
to baseline levels [44]. However, the data demonstrate a large
interstudy variability in response to the treatment that is
possibly due to the dose or ratio of n-3 fatty acids, the dura-
tion of study, the health status, diet, and other confounding
factors. The large heterogeneity within studies with n-3
fatty acids supplementation for the response to triglycerides
is likely to be attributable to genetic variability within the
study population. Nevertheless, these intervention studies
are largely short term and involved frequently higher dose of
n-3 fatty acids as compared to the clinical outcome studies.
Furthermore, more studies are needed to determine whether
there exist speciﬁc genotypes that may beneﬁt to a greater
extent from n-3 fatty acids for hypotriglycerolaemic eﬀects.
Clinicalstudiesalsoneedtodeterminewhetherthereduction
in CVD risk factors is due to EPA, DHA, or the combination
of both and the dosage of the eﬀective components
[31].
4.2. Fruit and Vegetables. There is a substantial amount of
literature that has consistently reported the beneﬁcial eﬀects
of diets rich in vegetables and fruits on CVD risk [45–48].
Conversely, inadequate consumption of fruit and vegetables
has been linked with higher incidence of CVD [49]. The
beneﬁts of fruit and vegetable intake appear to be dose
related. In addition, frequency of fruit and vegetable intake
has been associated with lower CVD risk [50, 51].
The mechanisms by which fruit and vegetables exert
their protective eﬀects are not entirely clear but likely
include antioxidant and anti-inﬂammatory eﬀects. Among
the possible explanations for this beneﬁcial eﬀect, fruits
and vegetables have been found to decrease susceptibility of
LDL particles to oxidation [52]. Potassium may also have
a protective role on the incidence of CVD as mounting
evidence indicates an inverse association between dietary
intake of fruits and vegetables and blood pressure [53,
54]. Several bioactive components in fruits and vegetables
such as carotenoids, vitamin C, ﬁber, magnesium, and
potassiumactsynergisticallyorantagonisticallytopromotea
holisticbeneﬁcialeﬀect.Thetotalityoftheevidencesupports
current dietary guidelines to increase fruit and vegetable
consumption to at least ﬁve.
Soluble ﬁbres including pectins from apples and citrus
fruits, β-glucan from oats and barley, and ﬁbres from
ﬂaxseed and psyllium are known to lower LDL-C [55].
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suggested to be the binding of bile acids and inhibition of
cholesterol synthesis. However, in the Health Professionals
Follow-Up Study, only cereal ﬁber, not fruit or vegetable
ﬁber, was inversely associated with risk of total stroke [56].
In contrast, several studies have not seen signiﬁcant pro-
tective eﬀects of fruit and vegetables on mortality, although
most show protective trends. These include a study of adults
in Maryland [57], the Kuopio Ischaemic Heart Disease Risk
Factor (KIHD) study among middle-aged Finnish men [58],
and the Adventist Health Study [59]. These studies may have
had insuﬃcient power, or inadequate ranges of intake to
observe signiﬁcant eﬀects.
4.3. Nuts and Legumes. Nuts are complex foods containing
cholesterol lowering mono- and polyunsaturated fatty acids,
arginine (a precursor to the vasodilator nitric oxide), soluble
ﬁber, and several antioxidant polyphenols [60]. Postprandial
vascular reactivity is characterized by decreased bioavail-
ability of nitric oxide and increased expression of pro-
inﬂammatory cytokines and cellular adhesion molecules
[61]. It is not surprising that the evidence supporting the
cardioprotective eﬀects of diets high in nuts is robust as
multiple mechanisms work together to reduce risk. Prospec-
tive data from the Physicians’ Health Study [62] indicated
reduced risk of sudden cardiac death associated with nut
consumptionoriginallyperceivedasbeingunhealthybecause
of their high-fat content.
Legumes are also complex foods rich in soluble ﬁbers
and polyphenols, as well as folic acid. Legumes were the
only food group predictive of survival among ﬁve long-
lived elderly cohorts in Japan, Sweden, Greece, and Australia
[63]. Furthermore, cumulative evidence from experimental
research indicates that cholesterol-lowering eﬀect of legumes
are probably due to the combined eﬀects of several bioactive
components, such as protein, soluble and insoluble ﬁbres,
and phytosterols [64]. A recent interventional trial in
humanshasshownthatlupinkernelﬂouraddedtobreadhas
alsoapositiveeﬀectonbloodpressure:boththeﬁbreandthe
protein were suggested to be responsible [65].
4.4. Whole Grains. Whole grain products contain intact
grain kernels rich in ﬁber and trace nutrients. They are
nutritionally more important because they contain phy-
toprotective substances that might work synergistically to
reduce cardiovascular risk.
The potential protective role of whole grains was ﬁrst
evaluated in the early 1970s [66]. Based on the results of the
prospective Iowa Women’s Health Study that demonstrated
cereal ﬁber had diﬀerent associations with total mortality,
depending on whether the ﬁber came from foods that
contained primarily whole grain or reﬁned grain [67].
A more recent meta-analysis based on seven qualifying
prospective cohort studies focused on whole grain consump-
tion and cardiovascular outcomes reported that the inverse
association between dietary whole grains and incident CVD
was strong and consistent across trials [68–71].
The mechanisms underlying the protective eﬀect of
whole grains on CVD risk include its eﬀects on insulin
sensitivity [28], blood pressure [72], lipids, and inﬂamma-
tion [73]. Although the anti-inﬂammatory mechanism is
not clear, it may be related to higher intakes of antioxidant
nutrients present in the germ of whole grains. As compared
to reﬁned grains, whole grains have a reduced glycemic
response following ingestion (i.e., the postprandial rise in
blood glucose is lessened), and reductions in postprandial
glucose surges have been associated with reduced reactive
oxygen generation after a meal and reduced postprandial
inﬂammation and CVD risk [28].
4.5. Soy Proteins. Soy is the main source of protein in the
Japanese diet, consumed in the form of miso soup and tofu.
Soy products are rich in polyunsaturated fatty acids, ﬁber,
vitamins and minerals, and low saturated fat content [74].
Prospective observational studies, initially in vegetarians
[75], then in Chinese women [76] ,a n di naJ a p a n e s e
population [77], have shown a reduction of total cholesterol
andLDL-Caswellasofischaemicandcerebrovascularevents
with a daily soy protein intake of more than 6g, compared
with less than 0.5g. A large number of clinical studies
were summarized in a meta-analysis [78] and conﬁrmed
that serum LDL-C concentrations are modiﬁed, the eﬀects
being related to baseline blood cholesterol levels. The results
of this meta-analysis were criticized recently, since more
recent studies appeared not to conﬁrm the very powerful
cholesterol-reducing eﬀect of soy proteins [74]. A recent
systematic review of available randomized controlled studies
mainly in subjects with moderate hypercholesterolaemia
conﬁrmed that the inclusion in the diet of a modest
amount of soy protein (25g) produces a highly signiﬁcant
reduction of total cholesterol and LDL-C levels equivalent
to ca. 6% LDL reduction [79]. Old studies were based
on the eﬀects in severely hypercholesterolaemic individuals,
whereas patients with hypercholesterolaemia in the very
highest range (>3350mg/L) have not been selected for
treatment in recent studies.
Soy products contain many isoﬂavonoids (genistein,
daidzein, glycitin) that are natural phytoestrogens able to
inhibit LDL oxidation, thus decreasing the risk of athe-
rosclerosis [80]. Several studies have reported a decrease
in susceptibility of LDL particles to oxidation with soy
protein consumption [81]. Furthermore, soy protein rich in
isoﬂavones reduced the susceptibility of LDL particles to oxi-
dationinhealthysubjects[82].Meta-analysesofrandomized
controlled trials have shown that soy isoﬂavones can lower
serumtotalandLDLcholesterolinhumans[83].Theeﬃcacy
of soy foods and isoﬂavone supplements on blood lipids
in clinical trials is less clear. These contradictory data may
be due to poorer responses in hypercholesterolemic subjects
compared to their control counterparts [74]. Recent clinical
trials in postmenopausal women with soy protein have also
shown similar discrepancies [84]. Clearly additional studies
areneededtodeterminewhethertherearediﬀerencesamong
whole food, soy protein and isoﬂavone extracts.
Comparisons between diﬀerent animal or clinical stud-
ies are hampered by the lack of standardization of soy
nomenclature, the diﬀerent formulations, doses, routes of
administration, time, and duration of exposure [85].J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
4.6. Dark Chocolate. Cocoa is a ﬂavonoid-rich food that has
been recently investigated for its possible role in the preven-
tion of CVD [86, 87]. In healthy adults, drinking ﬂavonoid-
rich cocoa may improve NO-dependent vasorelaxation and
ﬂow-mediated dilation in the brachial arteries [88]. Admin-
istration of dark chocolate in essential hypertensives reduced
ambulatory blood pressure and serum LDL-C levels whereas
white chocolate had no eﬀects [89]. Furthermore there was
ac l e a rr e d u c t i o no ft h eb l o o dc h o l e s t e r o ll e v e l sa sw e l la sa
signiﬁcant rise of HDL cholesterol in addition to a marked
reduction of circulating oxidized LDL [90].
4.7. Coﬀee and Tea. The active constituents of coﬀee appar-
ently responsible for cardioprotective eﬀect are diterpenes,
such as kahweol and cafestol. Coﬀee consumption may
possibly reduce the risk of myocardial infarction, but data
are as yet inconclusive [91, 92]. A dose-response decrease in
cardiovascular risk and heart disease mortality was reported
for a daily caﬀeine intake in patients with type 2 diabetes
[93, 94].
Green tea consumption appears to protect from CVD
[95], but results are again inconsistent. It has been reported
inameta-analysisthattheincidenceofmyocardialinfarction
amongindividuals whoconsumedthree cupsofteadailywas
notstatisticallysigniﬁcantandtherehasbeenlargevariability
across studies [96]. There were regional diﬀerences in this
meta-analysis, with increasing tea consumption associated
with an increased risk for CHD in the United Kingdom and
for stroke in Australia, whereas the risk decreased in other
regions, particularly in continental Europe. The hypothesis
that addition of milk to tea (as typically done in United
Kingdom and Australia) abolishes its plasma antioxidant
potential may only partially explain these geographic diﬀer-
ences.
5.BioactiveDietaryCompounds with
CardioprotectivePotentials
Early research evaluated the beneﬁts of plant-derived foods
based on their vitamin C, vitamin E, and carotenoid content
[24]. More recent work pointed out correlation of beneﬁts
with individual compounds [97]. However, the eﬀects noted
by testing them alone may be related to the synergistic
action of the myriad of other bioactives present in source
materials [98]. The main doubt about their eﬃcacy, whether
they should be consumed in a whole food diet or provided
in a supplemental form remains to be answered and will
be discussed in what follows. In each family of bioactive
compounds there are usually many members that are present
as discussed in following.
5.1. Phytochemicals. Plant foods contain many bioactive
compounds known as “phytochemicals.” Some groups of
phytochemicals which have or appear to have signif-
icant health potentials are carotenoids, phenolic com-
pounds (ﬂavonoids, phytoestrogens, phenolic acids), phy-
tosterols and phytostanols, tocotrienols, organosulfur com-
pounds, and nondigestible carbohydrates (dietary ﬁber and
prebiotics). Isoﬂavones are found in high concentration
in soybean, soybean products (e.g., tofu), and red clover.
Lignans are mainly found in ﬂaxseed.
5.1.1. Polyphenol Compounds. P o l yp h e n o l sh a v eb e e ns h o w n
in in vivo studies to exert antiatherosclerotic eﬀects in the
early stages of atherosclerosis development (e.g., decrease
LDL oxidation); improve endothelial function and increase
nitric oxide release (potent vasodilator); modulate inﬂam-
mation and lipid metabolism (i.e., hypolipidemic eﬀect);
improve antioxidant status; protect against atherothrom-
botic episodes including myocardial ischemia and platelet
aggregation (Perez-Jimenez and Saura-Calixto, 2008) [99].
5.1.2. Flavonoids. Plant-derived ﬂavonoids are the most
common group of polyphenols in the human diet, and are
containedinvegetablesandfruitsaswellasinbeveragessuch
ascocoa,tea,andwine.Someisoﬂavoneslikelignansarephy-
toestrogens, a group of nonsteroidal plant constituents that
elicit estrogen-like biological response. They are associated
as minor components with dietary ﬁber in dietary items like
oilseeds, cereal grains, vegetables, fruits, and legumes. Like
other phenolic compounds, phytoestrogens have antioxidant
activity, and like estrogens, they can inﬂuence lipoprotein
metabolism and enhance vascular reactivity.
Intake of ﬂavonoids has been associated with decreased
cardiovascular mortality and general mortality among
elderly Dutch individuals [100]. Several prospective studies
have reported inverse associations between ﬂavonoid intake
and CVD incidence or mortality [101–103]. Within the
cardiovascular protective mechanisms of ﬂavonoids, sev-
eral mechanisms have been proposed to explain the anti-
inﬂammatory properties of ﬂavonoids. These include their
antioxidant activity and their properties as metal chelators,
for transitional elements such as copper and iron that
catalyze lipid oxidation; inhibitors of platelet aggregation;
modulation of the activity of eicosanoid generating enzymes
in inﬂammatory cells enhancers of nitric oxide synthesis;
lowering of superoxide production; beneﬁcial eﬀects on lipid
proﬁle [104, 105] and modulation of proinﬂammatory gene
expression [97, 106, 107].
A systematic review of the eﬀectiveness of diﬀerent
ﬂavonoid subclasses and ﬂavonoid-rich foods on CVD con-
cluded that some ﬂavonoid-rich foods, including chocolate
or cocoa, red wine or grape, and green or black tea
m a yh a v es o m em e a s u r a b l ee ﬀects on CVD risk factors,
including a reduction in blood pressure and a favorable
inﬂuence on endothelial function [108]. Nevertheless, there
still exists uncertainty as to whether or not ﬂavonoids are the
only bioactive compounds mediating the enhanced vascular
reactivity. This is in part due to the fact that ﬂavonoid-rich
food and plant extracts contain many potentially bioactive
compounds, and information ensuing from investigations
in humans using speciﬁc, chemically pure ﬂavonoids is
rare. Therefore, it cannot be completely excluded, that the
observed eﬀects on vascular function may potentially, at
least in part, be related to compounds other than ﬂavonoids
contained in these foods/extracts. It should be noted that no
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eﬃcacy of isoﬂavones in reducing the incidence of CVD and
breast cancer and in preventing the loss of bone mineral
density in menopausal women.
5.1.3. Plant Sterols and Stanols. Plant sterols or phytosterols
are structurally similar and functionally analogous to the
animal sterol, cholesterol. A less abundant class of related
compounds is the plant stanols or phytostanols, which are
completely saturated forms of phytosterols. Dietary sources
include vegetable oils, nuts, seed and grains, butthe amounts
are often not large enough to have signiﬁcant cholesterol-
lowering eﬀects [109]. Also they have been incorporated in
foods with higher fat content, such as spreads (margarines)
and salad dressings. Phytosterols and phytostanols inhibit
intestinalabsorptionofcholesterol[110].HDLand/orVLDL
were generally not aﬀected by stanols/sterols intake. Yet,
eﬀects of sterols/stanols on LDLs have been found to be
additive to diets and/or cholesterol-lowering drugs [111].
This has been the basis for the development of phytosterol-
enrichedfunctionalfoods.Similareﬃcacyhasbeenobserved
between plant sterols and stanols when they are esteriﬁed,
which is the form added to foods [112]. Because plant sterols
and stanols can reduce fat-soluble vitamins, it is necessary
to consume plant sterols and stanols with an appropriate
intake of fruit and vegetables, including carotenoids [113].
There are also concerns about margarines containing plant
sterols and stanols, related to the energy intake associated
with consuming >2g daily [114].
5.1.4. Vitamin C. The powerful antioxidant functions of
vitamin C serve to reduce tissue reactive oxygen species
concentrations, which in the atherosclerotic condition help
prevent endothelial dysfunction, inhibit vascular smooth
muscle proliferation, and reduce oxidized LDL cholesterol
[115]. Several prospective studies have assessed the role of
vitamin C, both dietary and supplemental, in CVD, with
mixed results [116]. Despite its role as an antioxidant,
vitamin C has been identiﬁed as a pro-oxidant under
conditions of high oxidative stress [117]. Most clinical
trials have incorporated vitamin C into a mixture including
vitamin E and β-carotene, with largely null results in relation
to CVD [118, 119]. Nutrients and bioactive compounds in
foods act synergistically or antagonistically in the complex
food matrix to deliver the established health eﬀects of foods.
5.1.5. Carotenoids. Carotenoids have been credited with
other health-promoting eﬀects: immune enhancement and
reduction of the risk of developing degenerative diseases
such as cancer, CVD, and cataract [120, 121]. These phys-
iological activities have been attributed to an antioxidant
property, speciﬁcally to the ability to quench singlet oxygen
and interact with free radicals [122]. The carotenoids,
particularly lycopene and beta-carotene, are other dietary
antioxidants that function to reduce oxidative stress in vivo
and blood markers of inﬂammation [123]. Evidence for
a role of carotenoids in CVD ﬁrst stemmed from studies
that showed that higher intakes of fruit and vegetables
were associated with lower risk of CVD [124]. However,
studies on the association between dietary carotenoids and
CVD risk have been inconsistent. Women who regularly eat
large amounts of lycopene, from tomato and derivatives,
are less prone to developing CVD, since this phytochemical
has the strongest antioxidant activities in the cardiovascular
system [125]. Results from the KIHD study conﬁrmed that
lower serum lycopene levels were associated with enhanced
risk of atherosclerosis in the common carotid artery [58].
These protective associations were not evident for other
carotenoids like lutein, zeaxanthin, or β-cryptoxanthin
[126]. Despite overwhelming evidence from epidemiological
studies on carotenoids role in CVD, clinical trials have failed
to demonstrate a beneﬁcial eﬀect [18, 127].
5.1.6. Vitamin E. In addition to its role as a free radical
scavenger, vitamin E is a potent anti-inﬂammatory agent,
especially at high doses [128]. Mounting evidence supports
the strong inverse association between plasma vitamin E and
CVD [129] as well as that between vitamin E intake and risk
of CHD [130]. Nevertheless, clinical trials failed to support
the role of vitamin E supplementation in preventing CVD
[131]. Subsequent meta-analyses and systematic reviews
of more than 90 trials showed similar null results [132,
133]. Most recently, a dose-response meta-analysis showed
increased risk of high-dose vitamin E (≥400IU/day) on total
mortality [17]. There are many potential explanations for
these largely negative eﬀects that include the use of the most
appropriate form and/or dose of vitamin E. This may be
essential to obtain eﬀective reduction of oxidative stress. As
with carotenoids, the contrast between observational and
interventional studies results suggests that the protective
eﬀects of α-tocopherol occur in the presence of other
nutrients, and, therefore, it is most eﬀective and safe when
obtained from foods.
5.2. Antioxidant Vitamin Supplementation. The term “dieta-
ry supplement” can be deﬁned as a product that is intended
to supplement the diet with one or more of the following
dietary ingredients: a vitamin, a mineral, a herb or other
botanical, an amino acid, intended for ingestion in pill,
capsule, tablet, or liquid form [134]. It should be noted that
nutraceuticals diﬀer from dietary supplements in the follow-
ing aspects: (1) nutraceuticals must not only supplement the
dietbutshouldalsoaidinthepreventionand/ortreatmentof
disease,and(2)nutraceuticalsareusedasconventionalfoods
or as sole items of a meal or diet [134].
In view of the detrimental role of free radicals and reac-
tive oxygen species in the pathophysiology of atherosclerosis,
supplementation with antioxidants (vitamins A, C, and E,
folic acid, β-carotene, selenium, and zinc) was expected to
be protective. Some supplements (e.g., marine n-3 FAs and
niacin) are eﬀective in improving CVD risk factors, whereas
others (like B-vitamins: folate, vitamin B12, vitamin B6,
antioxidants; vitamin E and selenium) despite promising
in vitro studies have shown little eﬀect on CVD mortality
and morbidity, and antioxidant supplements may even have
adverse eﬀects.
Epidemiologic studies have reported that a high dietary
intake of foods rich in vitamin E [21], vitamin C [135],
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the incidence of CAD. Nevertheless, ﬁrm recommendations
to take antioxidant supplements to treat or prevent CVD
or metabolic diseases require evidence derived from ran-
domized controlled trials with vitamin supplements, which
were found to be disappointing [136]. Indeed, only one trial
has shown a reduction in myocardial infarction and cardiac
events [137], whereas all the others have shown no eﬀect
or detrimental eﬀects. Within ﬁve trials, such antioxidant
supplementation was associated with increased all-cause
mortality and two have shown higher risk of fatal CHD
(ATBC and CARET). Indeed, those controversial results by
no means invalidate the role of oxidative stress in CVD;
rather, they suggest that very high supplementation with
antioxidant vitamins may not represent an optimal strategy
to prevent vascular damage induced by oxidative stress and
lipidoxidation.Severalfactorsoughttobeconsidered,which
may have contributed to cloud the results of clinical trials,
like choosing the optimal dose and form of vitamins, the use
of single vitamin(s) or in combination, and so forth [138].
6.DietaryPatternsandReduced Riskof
ChronicDiseases
Eating habits and dietary trends have health, environmental,
and social impacts. Some diet plans demonstrated the ability
to reduce cardiovascular risk [139]. Despite the high levels
of interest in the diet and health relationship, the traditional
approach in nutritional epidemiology has mainly focused
on the eﬀects of individual nutrients or foods. However,
individualsdonotconsumenutrientsinisolationbut,rather,
meals consisting of a variety of foods in combinations of
nutrients that are likely to be interactive or synergistic.
Indeed much less concern has been focused on dietary
patterns because of their complex nature. The mechanisms
by which these diets reduce inﬂammatory risk are not
well understood but may relate to high intakes of food
items containing antioxidant nutrients and polyphenols that
reduce free radicals concentrations throughout tissues.
Consuming patterns of food vary signiﬁcantly across
nations, andthis might contributediﬀerentlyto the apparent
diﬀerences in the health of populations on the continent.
6.1. Mediterranean Diet. The Mediterranean diets contain
highlevelsoffruits,vegetables,cereals,beans,nutsandseeds,
and olive oil, with little red meat and dairy products. Fish
and poultry are consumed in low-to-moderate amounts;
and wine is consumed in moderation. They have received
great attention and numerous reports have demonstrated
low rates of chronic disease among populations known to
consume these diets [140]. Moreover, clinical trials have
conﬁrmed their cardiovascular protective eﬀects and their
eﬀectiveness to reduce inﬂammatory markers in high-risk
populations[13,141,142].SeveralMediterraneandietfoods,
including polyunsaturated fat products, vegetables, fruit,
whole grains, legumes, and low glycaemic index starchy
foods with functional properties may protect against type
2 diabetes [143]. They were also shown to reduce serum
homocysteine concentrations and consequently the risk of
coronary events, especially in high-risk individuals [144].
Olive oil (which induces a high ratio of monounsaturated
to saturated lipids) appears to be chieﬂy responsible for
the apparent protection oﬀered by the Mediterranean diet
against hypertension [145]. The high antioxidant content of
plant foods and olive oil may also contribute to the health
of the vascular system. However, it has been indicated in a
recent review that not all components of the Mediterranean
diet are equally protective [146]. Therefore, the convincing
evidence for the protective role of the Mediterranean diet
provided by the Lyon Diet Heart Study [141] needs to
be replicated in primary prevention trials as well as the
conduction in non-Mediterranean populations to determine
if the favorable eﬀects transfer to other groups.
6.2. DASH Diet. The Dietary Approaches to Stop Hyper-
tension (DASH) trial reported that a diet rich in ﬁsh, fruit,
vegetables, whole grains, and nuts and low in fat dairy foods
signiﬁcantly lowered systolic blood pressure in patients with
isolated systolic hypertension [147]. This dietary pattern also
limits saturated fat, red meat, sweets, and sugar-containing
beverages. Consistent weight loss induced by a very low
caloric diet improves vasodilatation-mediated blood ﬂow,
an eﬀect associated with decreased glucose blood levels
[148].Regularphysicalexercise,decreasedsalt(NaCl)intake,
moderate alcoholic ingestion, and an increase in dietary
potassium constitute evidence-based strategies to reduce
blood pressure by DASH diet.
Because hypertension is a CVD risk factor, several
prospective cohort studies have examined associations
between adherence to a DASH dietary pattern and incident
CVD events [10, 149, 150]. In addition to its eﬀects on
blood pressure and incident CHD, the DASH diet appears to
have beneﬁcial eﬀects on several CVD risk factors, including
total cholesterol, LDL-C [151], inﬂammation [149], and
homocysteine [152]. As a whole, the evidence for the
protective role of the DASH dietary pattern in prevention of
CVD is strong.
6.3. Portfolio Diet. Step I and Step II diets are early examples
of dietary strategies recommended for the clinical manage-
mentofhighbloodcholesterol[153].TheStepIdietrequires
a total fat intake of less than 30% of total calories, with
saturated fatty acids contributing to less than 10% of total
calories and cholesterol less than 300mg/day. For individuals
who require a more aggressive approach to meet their LDL-
C goals, the Step II diet, which lowers saturated fatty acids
to less than 7% of total calories and cholesterol to less than
200mg/day, is recommended.
Current recommendations for CVD risk reduction con-
tinue to focus on LDL-C as a major therapeutic target.
The National Cholesterol Education Program (NCEP) Adult
Treatment Panel (ATP) III guidelines recommend therapeu-
tic lifestyle changes for individuals whose LDL-C levels are
above goal (2001). LDL-C lowering can also be achieved by
adding other dietary components, speciﬁcally plant sterols,
viscous ﬁbers, soy protein, and almonds. This combination
of dietary components has been labeled the Portfolio diet
[154]. Another important attribute of the Portfolio diet is10 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
its beneﬁcial eﬀects on C-reactive protein lowering, a strong
independent predictor of cardiovascular risk [155].
6.4. Vegetarian Diet. A vegetarian diet, devoid of meat and
ﬁsh, and high in fruits, vegetables, and nuts, rich sources
of the antioxidant nutrients and polyphenols, contribute
to the anti-inﬂammatory potential of these diets. In terms
of micronutrients content, vegan diets are usually higher
in magnesium, folic acid, vitamins C and E, iron, and
phytochemicals, and they tend to be lower in n-3 fatty
acids, vitamin D, calcium, zinc, and vitamin B-12. Much
of this beneﬁt is likely related to the low body weights, low
blood pressure, and low blood cholesterol concentrations
generally observed for vegetarians due to their lower intakes
of saturated fats, cholesterol, and calories. Vegetarians are
reported to have a lower risk of dying from ischemic heart
disease [156] and have a reduced all-cause mortality [57].
6.5. Okinawan Diet. Equally notable is the wide variation
in other aspects of healthy diets such as macronutrient
intake, represented most notably by the healthy Okinawan
diet, which is low in fat and high in carbohydrates (mostly
from vegetable sources). This suggests that low-energy,
nutrient-dense diets with high-quality carbohydrates may
be beneﬁcial for reducing the risk of CVD among many
chronic diseases [157]. The cardioprotective beneﬁt of
Okinawan diet is ascribed, in part, to the low consumption
of saturated fat. Other possible mechanisms, such as the
high contents of phytochemicals, high antioxidant intake,
and low glycemic load in this diet, are also likely to be
contributing to decreased risk for CVD and some cancers
through multiple mechanisms, including reduced oxidative
stress. A comparison of the nutrient proﬁles of the previous
dietary patterns shows that the traditional Okinawan diet is
the lowest in fat intake, particularly in terms of saturated
fat, and highest in carbohydrate intake, in keeping with the
very high intake of antioxidant-rich yet calorie-poor orange-
yellowrootvegetables,suchassweetpotatoes,andgreenleafy
vegetables [158]. The longevity of Okinawan populations
suggests that such a diet may even help to slow the aging
process itself [159].
7. Conclusion
The relationship between dietary factors and CVD has been
a major focus of health research for almost half a century.
Epidemiological and clinical studies indicate that the risk
of CVD is reduced by a diet rich in fruits, vegetables,
unreﬁned grains, ﬁsh and low-fat dairy products, and low in
saturated fats and sodium [11]. Other foods such as mono-
and polyunsaturated fats, brans, nuts, plant sterols, and soy
proteins have all been shown to have a favorable eﬀect on
lipid proﬁle and blood pressure [9, 161].
Novel dietary approaches to cardiovascular prevention
are of major signiﬁcance in clinical research and practice.
However, nutrition is a very complex research topic and it
is not clear whether an individual component of the diet
or a combination of nutrients and dietary habits may be
responsible for any cardioprotective eﬀects. The advances
in the knowledge of both the disease processes and healthy
dietary components have provided new avenues to develop
dietary strategies to prevent and/or to treat CVD. It is
now evident, based on the extensive scientiﬁc evidence,
that functional foods have broad ranging physiologic eﬀects
in vivo that lessen inﬂammatory cascades and vascular
reactivity. These eﬀects are as powerful as pharmaceutical
interventions, yet much safer. Although many of these
functional foods have been found to have high therapeutic
potential, future studies should include well-designed clini-
cal trials assessing diﬀerent combinations of these nutrients
to realize possible additive and/or synergistic eﬀects on
health outcomes. Many functional foods have antioxidant
and anti-inﬂammatory activities, by mechanisms that may
require further investigation. Therefore, these functional
foods should be incorporated into a healthy diet to provide
cardiovascular beneﬁts and hence lower cardiovascular risk.
Emerging evidence for a potential role of antioxidant
vitamins in atherosclerotic progression implies that the
eﬀect of micronutrients is complex and not likely due to a
single nutrient in isolation. Therefore, the use of vitamin
supplements is not recommended. Rather, eﬀorts should be
targetedtoincreasingtheconsumptionofvitamins-richfruit
and vegetables.
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